+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others)

  • ID: 2789941
  • Report
  • Region: Global, United States
  • 195 Pages
  • Kalorama Information
1 of 4
With Fingers Crossed, Report Says Biosimilars Poised For Growth

FEATURED COMPANIES

  • 3SBio, Inc
  • Bio Sidus S.A.
  • Boehringer Ingelheim Gmbh
  • Epirus Biopharmaceuticals
  • Merck & Company
  • Samsung Bioepis Co Ltd
  • MORE
This study, The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment.

Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market.

While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following:

- Marketed Biologics with Expired Patents
- Marketed Biologics with Active Patents
- Cost Savings From Biosimilar Use
- World Biosimilar Market Potential by Region 2010-2017
- Biosimilars Pipeline by Company and Product Type
- Scientific Differences of Pharmaceuticals and Biopharmaceuticals
- Market Share of Biosimilar Sales in Comparison to Brand Sales
- World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other)

The study has focused on the market for products which have lost patent in key markets. Projections were made based on the progress that is occurring within the generic arena in terms of capabilities, capital, interest, and development of biopharmaceuticals. Biopharmaceuticals that have lost patent protection and are the first products produced by generic companies are identified.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3SBio, Inc
  • Bio Sidus S.A.
  • Boehringer Ingelheim Gmbh
  • Epirus Biopharmaceuticals
  • Merck & Company
  • Samsung Bioepis Co Ltd
  • MORE
1. Executive Summary

- Introduction
- Scope And Methodology
- Size And Growth Of The Market
The World Market For Biosimilars
- Trends Affecting The Market
- Market Outlook

2. Introduction And Overview

- Biosimilars Overview
- Biopharmaceutical Industry And Approval Process
Genetic Engineering
Patent Approval
- Regulations For Biopharmaceuticals
- History Of The Prescription Generic Pharmaceuticals Industry
- History Of The Generic Approval Process
- Regulation Of Prescription Generic Pharmaceuticals
- Biopharmaceuticals
- Areas Of Treatment For Biopharmaceuticals

3. Biosimilar Pharmaceuticals For Expired Biologic Patents

4. Biosimilar Pharmaceuticals For Future Expired Biologic Patents

5. Issues And Trends

- Overview
- Worldwide Regulatory And Legislative Issues
Europe
United States
Japan
Rest Of World
- Asia And Biosimilars
India
China
South Korea
- Scientific Issues
- Patent Issues
- Pricing Issues
- Barriers To Entry
- Biosimilar Development Paradigm Shift
- Innovator Strategies And Challenges
- Bulk Suppliers And Contract Manufacturing
- Bioequivalence Issues
- International Issues
- Low-Cost Branded Hgh
- Biosimilars And Health-Care Spending
- Patent Challenges
- Intellectual Property

6. Market Summary

- Total Market Size And Forecast
- Market Size And Growth
- Regional Market Analysis
- Biologic Class Market Analysis
- Market Potential
- Competitor Analysis

7. Corporate Profiles

- 3Sbio, Inc
- Actavis, Inc.
- Apotex, Inc.
- Beijing Four Rings Biopharmaceutical Co Ltd
- Biocad
- Biocon Ltd .
- Biopartners Gmbh
- Bio Sidus S.A.
- Bioxpress Therapeutics S.A
- Boehringer Ingelheim Gmbh
- Celltrion, Inc.
- Dong-A Pharmaceutical
- Dr. Reddy'S Laboratories Limited
- Epirus Biopharmaceuticals
- Gedeon Richter
- Harvest Moon Pharmaceuticals Usa, Inc
- Hospira, Inc.
- Kyowa Hakko Kirin Co., Ltd.
- Merck & Company
- Momenta Pharmaceuticals Inc
- Phage Pharmaceuticals, Inc.
- Ranbaxy Laboratories Limited
- Reliance Genemedix Plc
- Reliance Life Sciences
- Samsung Bioepis Co Ltd
- Sandoz International Gmbh
- Sandoz International Gmbh
- Stada Arzneimittel Ag
- Teva Pharmaceutical Industries, Ltd.
- Wockhardt Ltd.
- Xiamen Amoytop Biotech Co Ltd.

Company Directory

List Of Exhibits

Table 1-1: Total World Biosimilar Market Potential 2010-2017
Figure 1-1: World Biosimilar Market Potential 2010-2017
Table 2-1: Scientific Differences Of Pharmaceuticals And Biopharmaceuticals
Table 3-1: Select Marketed Biologics With Expired Patents
Table 4-1: Select Marketed Biologics With Active Patents
Table 4-2: Number Of Select Biosimilar Products In Development 2012
Table 5-1: Biosimilars Approved In Eu
Figure 5-2: Cost Of Selected Biopharmaceuticals
Table 5-2: Estimates Of Treatment Cost Per Patient Of Selected Biopharmaceuticals
Table 5-3: Patent Challenges By Company 2012
Table 6-1: Total World Biosimilar Market Potential 2010-2017
Figure 6-1: World Biosimilar Market Potential 2010-2017
Table 6-2: World Biosimilar Market Potential By Region 2010-2017
Figure 6-2: World Biosimilar Market Potential By Region 2010-2017
Table 6-3: The World Market Potential For Biosimilars By Biological Class 2010-2017*
Figure 6-3: The World Market Potential For Biosimilars By Biological Class 2010-2017 (Millions)
Figure 6-4: The World Market Potential For Biosimilars By Biological Class Market Share 2012
Figure 6-5: The World Market Potential For Biosimilars By Biological Class Market Share Forecast To 2012
Figure 6-6: The World Market Potential For Biosimilars By Biological Class, Market Share 2017
Table 6-4: Market Share Of Biosimilar Sales In Comparison To Brand Sales, 2012 Estimates
Table 6-5: Biosimilars Pipeline By Product Type
Table 6-6: Market Share Of Early Leaders In The World Biosimilar Market, 2012
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • 3SBio, Inc
  • Bio Sidus S.A.
  • Boehringer Ingelheim Gmbh
  • Epirus Biopharmaceuticals
  • Merck & Company
  • Samsung Bioepis Co Ltd
  • MORE
It's not the first prediction that has been made about the market for generic forms of biopharmaceutical drugs, but according to this report a multi-billion dollar market for biosimilars will arrive in the next five years. The healthcare organization says it's in almost everyone's interest - payors, governments, providers and patients seeking low-cost alternatives to the most expensive and effective therapies. The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, Monoclonal Antibodies, Others), predicts a market of nearly $5 billion dollars in the next five years.

The generic biologic drug market presents many more challenges than the traditional generic market and regulatory restrictions remain. Generic biological drugs are more difficult to produce and a few firms have the expertise. Unlike generics, they are not the exact same as the brand, they have a similar structure and function. Insulin, blood products and monoclonal antibodies (mAbs) are expected to show the most potential for generic equivalent products with blood products leading in revenues. The EU is the first in the world to have defined a policy and legal framework for biosimilars. Absence of such regulation and biosimilars approval process in other countries, in particular in the United States, can lead to a competitive advantage to the EU biosimilars industry, according to the report.

The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, Monoclonal Antibodies, Others).contains predictions of biosimilar markets in certain biologic drug segments, as well as market by regions. The report contains specific forecasts for each type of biopharmaceutical and breaks out forecasts by region.
Note: Product cover images may vary from those shown
5 of 4
- 3SBio, Inc
- Actavis, Inc.
- Apotex, Inc.
- Beijing Four Rings Biopharmaceutical Co Ltd
- Biocad
- Biocon Ltd .
- Bio Sidus S.A.
- BioXpress Therapeutics S.A.
- Boehringer Ingelheim Gmbh
- Celltrion, Inc.
- Dong-A Pharmaceutical
- Dr. Reddy's Laboratories Limited
- Epirus Biopharmaceuticals
- Gedeon Richter
- Harvest Moon Pharmaceuticals USA,
- Hospira, Inc.
- Kyowa Hakko Kirin Co., Ltd.
- Merck & Company
- Momenta Pharmaceuticals Inc
- Phage Pharmaceuticals, Inc.
- Ranbaxy Laboratories Limited
- Reliance GeneMedix PLC
- Reliance Life Sciences
- Samsung Bioepis Co Ltd
- Sandoz International GmbH
- STADA Arzneimittel AG
- TEVA Pharmaceutical Industries, Ltd.
- Wockhardt Ltd.
- Xiamen Amoytop Biotech Co Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll